



# NIH funding opportunities



Faculty of Medicine and Health Sciences: Research Development and Support 05 Nov 2018 (#34)

[Click on blue [hyperlink](#) for further information]

The NIH funding opportunities listed below are only a **selection** of pre-screened, currently open health funding opportunities for which **South African institutions are eligible to apply**. For a comprehensive selection of NIH funding opportunities, please visit [www.grants.nih.gov](http://www.grants.nih.gov) or [www.sun.ac.za/RDSfunding](http://www.sun.ac.za/RDSfunding) (current & archive).

**Confirm your intent to apply ASAP, but not later than 30 days before the submission date.**

Contact: RGMO Pre-Awards [cdevries@sun.ac.za](mailto:cdevries@sun.ac.za)

## Important Notices

**Update to NIH Management of Genomic Summary Results Access ([NOT-OD-19-023](#))** In order to gain stakeholder feedback about the specific proposed data management update, NIH released a 30-day [Request for Comment](#) (RFC) on September 20, 2017, and, in response to stakeholder requests, reopened the RFC for a second 15-day [RFC](#) on November 27, 2017. Because the workshops and previous RFI largely captured the perspective of researchers, a particular attempt was made to reach out to research participants and the broader patient community to request their feedback. Through the RFC, NIH sought stakeholder input on: risks and benefits to broad sharing of GSR from most genomic studies, including use of the click-through agreement affirming responsible use; risks and benefits to maintaining GSR from “sensitive” studies in controlled-access; the proposed method for designating studies as “sensitive”; and, general feedback on other topics within the proposed update.

### 1. Human Islet Research Network - Consortium on Targeting and Regeneration (HIRN-CTAR) (Clinical Trial Not Allowed)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [\(RFA-DK-18-014\)](#)

**Type:** U01

**Application Due Date:** February 26, 2019. Apply by 5:00 PM local time of applicant organization.

**Funding Opportunity Announcement:** This Funding Opportunity Announcement (FOA) solicits applications for the Consortium on Targeting and Regeneration (CTAR) that supports the development of innovative strategies to increase or protect functional human beta cell mass in patients with Type-1 Diabetes (T1D) through the controlled manipulation of beta cell replication, islet cell plasticity, and the reprogramming of pancreatic non-beta cells into beta-like cells, or through shielding the residual beta cell mass from the autoimmune environment. CTAR is part of the Human Islet Research Network (HIRN).

**Budget:** National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) intends to commit \$2.5 million for FY 2019 to fund 3-5 awards. Application budgets are limited to \$550,000 direct costs per year. The maximum project period is 4 years.

### 2. Lewy Body Dementia Center Without Walls (CWOW) (Clinical Trial Not Allowed)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [\(RFA-NS-19-013\)](#)

**Type:** U54

**Application Due Date:** January 4, 2019. Apply by 5:00 PM local time of applicant organization.

**Funding Opportunity Announcement:** This FOA invites applications that will systematically and comprehensively characterize alpha-synuclein and amyloid-beta subspecies present in human Lewy Body Dementia (LBD) post-mortem brain tissue, identify toxic subspecies and potential mechanisms of toxicity, and characterize any interactions between the proteins that may contribute to increased toxicity and/or explain selective vulnerabilities of cells/circuits. Applications are required to include at least 3 hypothesis-driven projects that address these goals, an administrative core, and other cores as appropriate. Applicants will be expected to focus on the use of human tissues. All applications will be expected to include plans for developing a publicly-available library of fully characterized alpha-synuclein and amyloid-beta subspecies found in LBD.

**Budget:** National Institute of Neurological Disorders and Stroke (NINDS) and (National Institute on Aging) NIA intend to fund an estimate of 1-3 awards, corresponding to a total of \$3,500,000 for fiscal year 2019. Future year amounts will depend on annual appropriations. Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is 5 years.

### 3. Building in vivo Preclinical Assays of Circuit Engagement for Application in Therapeutic Development (Clinical Trial Not Allowed)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [\(RFA-MH-19-235\)](#)

**Type:** R01

**Application Due Date:** February 4, 2019. Apply by 5:00 PM local time of applicant organization.

**Funding Opportunity Announcement:** The overall goal of this Funding Opportunity Announcement (FOA) is to identify, in animals, in vivo neurophysiological and behavioral measures for use as assays in the early screening phase of treatment development. The FOA will support efforts to optimize and evaluate measures of neurophysiological and behavioral processes that may serve as surrogate markers of neural processes of clinical interest based on available knowledge of the neurobiology of mental illnesses. The screening assays thus developed from this FOA are expected to build upon systems neurobiology and clinical neuroscience to enhance the scientific value of preclinical animal data contributing to a therapeutic development pipeline by assessing the impact of therapeutic targets and treatment candidates on neurobiological mechanisms of clinical relevance to mental illnesses.

The objectives of the FOA will be accomplished by supporting basic and translational neuroscientists who are committed to improving the efficiency and scientific value of the therapeutic development pipeline by advancing the discovery of in vivo physiological and behavioral measures reflecting circuit engagement as tools for early phase target validation and therapeutic screening for mental illness treatment development. The efforts supported by this initiative focus on measures in animals as a first step in generating translational assay measures that are adaptable across early therapeutic screens in animals to evaluation in humans. As such, this FOA may be considered a prequel to build a suite of assays that are evaluated in future projects for coherence of assay performance between the preclinical species and healthy humans. In summary, this FOA will support efforts to improve the tool kit of assays available for early phase testing of novel therapeutic agents by incorporating measures proximal to neural systems that impact mental health.

**Budget:** National Institute of Mental Health (NIMH) intends to commit \$2 million direct costs in FY 2019 to fund 5-7 awards. Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 4 years maximum.

### 4. Engaging Men in HIV Testing, Prevention, and Care (Clinical Trial Optional)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [\(PA-19-042\)](#)  
[\(PA-19-050\)](#)

**Type:** R01  
R21

**Application Due Date:** [Standard AIDS dates](#) Apply by 5:00 PM local time of applicant organization.

**Funding Opportunity Announcement:** The purpose of this Funding Opportunity Announcement (FOA) is to develop and test strategies to increase the engagement of men in HIV prevention and care within global settings and among US domestic populations who have evidenced lower rates of engagement and retention in HIV prevention and care. The R01 mechanism is intended to support a discrete, specified, circumscribed project to be performed by the named investigator(s) in an area representing his or her specific interest and competencies. The R21 Exploratory/Developmental Grant supports studies that may involve considerable risk but may lead to a breakthrough in a particular area; or to the development of novel techniques, agents, methodologies, models; or applications that could have a major impact on a field of biomedical, behavioral, or clinical research.

**Budget:** Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years. **R21** - The combined budget for direct costs for the two-year project period may not exceed \$275,000. No more than \$200,000 may be requested in any single year.

### 5. Advancing Research in Augmentative and Alternative Communication (AAC) (Clinical Trial Optional)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [\(PA-19-046\)](#)

**Type:** R21

**Application Due Date:** [Standard dates](#) and [Standard AIDS dates](#) Apply by 5:00 PM local time of applicant organization.

**Funding Opportunity Announcement:** This funding opportunity announcement (FOA) solicits Research Project Grants (R21) applications on augmentative and alternative communication (AAC) to advance our scientific knowledge in the evaluation and treatment of individuals with complex communication needs (CCN) or with severe speech and physical impairments (SSPI). AAC is a set of tools and strategies that an individual uses to solve everyday communicative challenges. This FOA is for R21s only and encourages a range of research inclusive of basic, clinical, and translational.

**Budget:** The combined budget for direct costs for the two-year project period may not exceed \$275,000. No more than \$200,000 direct costs may be requested in any single year.

### 6. Advancing Research in Augmentative and Alternative Communication (AAC) (Clinical Trial Optional)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** [\(PA-19-047\)](#)

**Type:** R01

**Application Due Date:** [Standard dates](#) and [Standard AIDS dates](#) Apply by 5:00 PM local time of applicant organization.

**Funding Opportunity Announcement:** This funding opportunity announcement (FOA) seeks Research Project Grants (R01) applications on Augmentative and Alternative Communication (AAC) to advance our scientific knowledge in the evaluation and treatment of individuals with severe speech and physical impairments (SSPI). AAC is a set of tools and strategies that an individual uses to solve everyday communicative challenges. This FOA is for R01s only and encourages a range of research inclusive of basic, clinical, and translational.

**Budget:** Application budgets are not limited but need to reflect the actual needs of the proposed project. The scope of the proposed project should determine the project period. The maximum project period is 5 years.

## 7. End-of-Life and Palliative Care Approaches to Advanced Signs and Symptoms (R21- Clinical Trial Optional)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** ([PAR-19-044](#))  
([PAR-19-045](#))

**Type:** R21  
R01

**Application Due Date:** [Standard dates](#) and [Standard AIDS dates](#) Apply by 5:00 PM local time of applicant organization.

**Funding Opportunity Announcement:** The purpose of this funding opportunity announcement (FOA) is to stimulate research to examine the multi-dimensional foundations, experiences and management of complex, advanced signs and symptoms at the end of life.

**Budget:** R21 - The combined budget for direct costs for the two year project period may not exceed \$275,000. No more than \$200,000 in direct costs may be requested in any single year. R01 - Application budgets are not limited but need to reflect the actual needs of the proposed project. The total project period for an application submitted in response to this funding opportunity may not exceed 5 years.

## 8. National Heart, Lung, and Blood Institute (NHLBI) TOPMed: Omics Phenotypes of Heart, Lung, and Blood Disorders (Clinical Trial Not Allowed)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** ([PAR-19-048](#))

**Type:** X01

**Application Due Date:** October 18, 2019 Apply by 5:00 PM local time of applicant organization.

**Funding Opportunity Announcement:** This Funding Opportunity Announcement (FOA) invites applications to use NIH-funded omics capacity to carry out studies of the genetic basis and/or omics signatures of common, complex heart, lung, and blood disorders, with strong interest in receiving applications on sickle cell and other rare blood disorders. Successful applicants will provide biospecimens for whole genome sequencing or other omics assays. No funding will be provided under this FOA. The omics data and related phenotypic data will be deposited in a public database such as dbGaP.

**Budget:** The number of projects granted access to omics assay resources is contingent upon the number of meritorious applications and the capacity of the omics centers. NHLBI intends to approve up to 10 projects. Not applicable. **Funds are not awarded** via this X01 resource access award. The maximum project period is 4 years.

## 9. Emerging Global Leader Award (Independent *Clinical Trial Required*)

**Letter of Intent:** 30 days prior to the application due date

**Hyperlink:** ([PAR-19-051](#))

**Type:** K43

**Application Due Date:** December 4, 2018; November 7, 2019; and November 4, 2020. Apply by 5:00 PM local time of applicant organization.

**Funding Opportunity Announcement:** This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary study to an existing trial, as part of their research and career development. Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion FOA PAR-17-001. The purpose of the Fogarty Emerging Global Leader Award is to provide research support and protected time (three to five years) to an early career research scientist from a low- or middle-income country (LMIC) who holds a junior faculty position at an LMIC academic or research institution, as defined by the World Bank (<http://data.worldbank.org/about/country-classifications/country-and-lending-groups>), including "low-income," "lower-middle-income," and "upper-middle-income" countries). This intensive, mentored research career development experience is expected to lead to an independently funded research career at the LMIC institution or in another LMIC. This Funding Opportunity Announcement (FOA) invites applications from LMIC scientists from any health-related discipline who propose career development activities and a research project that is relevant to the health priorities of their country under the mentorship of LMIC and U.S. mentors.

**Budget:** NIH will contribute up to \$75,000 (for a minimum of 75% effort or 9 person months) per year toward the salary of the career award recipient. Further guidance on budgeting for career development salaries is provided in the SF424 (R&R) Application Guide. See also [NOT-OD-17-094](#). The total NIH contribution to salary, however, may not exceed the legislatively mandated salary cap. See: [http://grants.nih.gov/grants/policy/salcap\\_summary.htm](http://grants.nih.gov/grants/policy/salcap_summary.htm). NIH will contribute up to \$30,000 per year toward the research development costs of the award recipient, which must be justified and consistent with the stage of development of the candidate and the proportion of time to be spent in research or career development activities. Research development costs include, but are not limited to, supplies, equipment, technical personnel, non-degree related tuition or registration fees for activities related to the proposed career development plan, fees for statistical and computational services, and travel to research sites, research meetings, or training, as detailed in Section IV. Salary for mentors, secretarial and administrative assistants, etc. is not allowed.

**Brief definitions of some NIH grant mechanisms:** [comprehensive list of extramural grant and cooperative agreement activity codes](#)